BEBT-507

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-08-18 — Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV): Multicenter open-label Phase I trial launched in polycythemia vera, with Ia dose-escalation followed by Ib dose-expansion to assess safety, tolerability, PK, pharmacodynamics, and preliminary efficacy, and to select a recommended Phase III dose (protocol announcement; no results yet). (novelty: 3)

Open questions

Related